Meeting
2016 ASCO Annual Meeting
Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.
Authors
David Cella
Northwestern University, Feinberg School of Medicine, Chicago, IL
David Cella , Viktor Gruenwald , Paul D. Nathan , Justin Doan , Homa Dastani , Fiona Taylor , Bryan Bennett , Michael DeRosa , Scott Berry , Kristine Broglio , Elmer Berghorn , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01668784
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4549)
DOI
10.1200/JCO.2016.34.15_suppl.4549
Abstract #
4549
Poster Bd #
171
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.
First Author: Robert J. Motzer
Poster
2016 ASCO Annual Meeting
Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.
First Author: Bernard J. Escudier
Poster
2016 Genitourinary Cancers Symposium
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
First Author: Robert J. Motzer
Poster
2023 ASCO Genitourinary Cancers Symposium
Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.
First Author: Saby George